Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

In this case report, a 45-year-old man with treatment-resistant androgenetic alopecia experienced hair regrowth during oral bicalutamide treatment but also suffered adverse effects leading to discontinuation, highlighting the need for further studies on the safety and role of androgen receptor blockade in hair loss.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

This article reviews the efficacy of Finasteride for treating female androgenic alopecia, highlighting increased hair counts and density but reports no new clinical results.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This review discusses the use of finasteride for treating androgenetic alopecia in men, noting its effectiveness in maintaining and regrowing hair on the scalp and top of the head.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This article discusses the familiarity of identifying male androgenetic alopecia but presents no new research findings.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

Dutasteride helps reduce male pattern hair loss, but may cause side effects like altered libido and erectile dysfunction.

This study discusses the difficulties in interpreting and communicating the association of 5α-reductase inhibitors with impaired libido and erectile dysfunction in men with benign prostatic hyperplasia due to the use of odds ratios instead of relative risks.

This review discusses treatments for various symptoms of polycystic ovary syndrome, including lifestyle changes, medical, and surgical interventions, but does not present new clinical results.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

This study found that finasteride and minoxidil act as hormone disruptors in mice, with finasteride having a more significant association with reproductive injuries, such as damage to the epididymis and reduced semen volume.

This article reviews the controversies that led to the establishment of the ISHRS and its impact on the evolution of hair transplantation, reporting no new clinical results.

This study found that finasteride may affect Ca 2+ signalling in human sperm by interacting with the PGE 1 -binding site, but its impact on fertilization requires further investigation.

This review highlights that various commonly prescribed medications for chronic conditions may impact male fertility by affecting hormone secretion, sperm production, ejaculation, erectile function, and libido, although conclusive evidence is limited to specific drug groups.

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

This review discusses the roles of hormonal pathways in regulating male sexual function, particularly highlighting the impact of testosterone, and reports no new research findings.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

In this randomized controlled trial, the nutritional supplement PPT5 α was associated with increased terminal hair percentages and improved self-assessed hair parameters in women with early-stage androgenetic alopecia.

This article discusses the need to investigate long-term effects of androgen manipulations independently of current levels, referencing Post-finasteride Syndrome as a relevant clinical example, and reports no new results.

In this study, the application of Dr. SKS Hair Booster Serum, containing micronutrients and multivitamins, significantly improved hair density and reduced hair fall in 1,000 patients with androgenetic alopecia over six months, with no major adverse events reported and 95% patient satisfaction.

This study found that finasteride significantly promoted hair growth compared to placebo in male patients with androgenic alopecia, but also noted a high incidence of sexual side effects.

Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.